Clinical studies have shown that carefully managing the blood glucose levels of patients in Intensive Care Units (ICUs), known as ‘Tight Glycemic Control’ (TGC), significantly reduces patient mortality, morbidity, and the length and cost of their stay. TGC requires constant monitoring of the patient’s glucose levels which to date has relied on inefficient, labour intensive and costly manual intervention by nursing staff. GlySure has automated this process by developing an intravascular sensor capable of continuously monitoring a patient’s glucose for the length of their stay in the ICU. The GlySure system comprises a monitor and a sterile disposable sensor which links seamlessly into a patient’s existing intravascular line without disrupting the clinician’s ability to monitor pressure, draw blood or administer medication through it.

Amadeus, alongside other experienced medtech investors Delta Partners and Patrick Paul, believed that the GlySure team with its successful history of working together to develop intravascular blood gas sensors for both Pfizer and Diametrics, could develop the technology needed to realize this $1bn market. Having successfully demonstrated the ability to continuously monitor glucose levels for the length of stay in ICU patients, GlySure is now rapidly preparing for regulatory trials in both the US and Europe. Anne Glover, who represents Amadeus on the Board said ‘We are excited by the early human results which demonstrate that GlySure’s sensor is accurate for at least 72 hours, which is longer than the average stay in the ICU. We believe GlySure can bring the improvement in real-time information needed for TGC to be widely adopted as a safe and efficient way of improving ICU outcomes’.